

Attorney Docket No.: 4394.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Serial No.: 09/325,603

Group Art Unit: 1652

Filed: June 3, 1999

Examiner: E. Slobodyansky

For: α -Amylase Mutants

AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed March 17, 2000, kindly amend the above-identified application as set forth below.

IN THE CLAIMS:

Cancel claims 72-75 without prejudice or disclaimer. Amend claim 71 under the provisions of 37 C.F.R. §1.121(a)(2)(ii) as follows:

71. (Twice amended) A method of producing a variant of a parent alpha-amylase having an altered property relative to the parent, wherein the parent alpha-amylase has the sequence of SEQ ID Nos: 2, 4, 6, or 13, or has a sequence at least 70% homologous to the sequence of SEQ ID Nos: 2, 4, 6, or 13 when homology is determined by the GAP program (Genetic Computer Group, Version 7.0) using default values for GAP penalties, said method comprising

(a) [modelling the parent alpha-amylase on an X-ray crystallographic three-dimensional structure of an alpha-amylase having the sequence of SEQ ID Nos: 2, 4, 6, or 13, or having a sequence at least 80% homologous to the sequence of SEQ ID Nos: 2, 4, 6, or 13 when homology is determined by the GAP program using default values for GAP penalties, to produce a modelled three-dimensional structure of

BEST AVAILABLE COPY

NOVO NORDISK OF NORTH AMERICA, INC.
405 LEXINGTON AVENUE, SUITE 6400
NEW YORK, NEW YORK 10174-6401

Telephone: (212) 867-0123

FAX: (212) 878-9655

CORPORATE PATENTS

TELECOPY

Page 1 Of 12 Page(s)

Please Hand Deliver The Following To:

TO : Ex. E. Slobodyansky

CC : _____

FROM : Gina MaldonadoDATE : 7/17/00MESSAGE : USSN: 09/325,603Dkt. 4394, 214-US

IF ANY PROBLEMS OCCUR, PLEASE CALL
LOREN HERNANDEZ (212) 867-0123
Fax. (212) 878-9655

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

BEST AVAILABLE COPY

Attorney Docket No.: 4394.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Serial No.: 09/325,603

Group Art Unit: 1652

Filed: June 3, 1999

Examiner: E. Slobodyansky

For: α -Amylase VariantsFILING OF CONTINUED PROSECUTION
APPLICATION (CPA) UNDER 37 C.F.R. §1.53(d)Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

This is a request for filing a continuation divisional [choose one] application under 37 CFR 1.53(d) of prior application number 09/325,603 filed on June 3, 1999, entitled α -Amylase Variants.

1. ☒ An Amendment is enclosed.
2. ☒ The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: $4 - 20 = 0 \times 18 =$	\$ 0
Independent Claims: $4 - 3 = 1 \times 78 =$	\$ 78.00
Total Fee:	\$768.00


3. ☐ Applicant hereby petitions for an extension of time under 37 CFR 1.136 for 1 month. If an additional extension of time is required, please consider this a petition therefor. The required extension fee is estimated to be \$110.
4. ☒ Please charge the required fee, estimated to be \$878, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this

BEST AVAILABLE COPY

sheet is enclosed.

Respectfully submitted,

Date: July 17, 2000


Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123